Targeted delivery of adenoviral vectors by cytotoxic T cells

Blood

Volumn 104, Issue 8, 2004, Pages 2272-2280

  Yotnda, Patricia ^a   Savoldo, Barbara ^b   Charlet Berguerand, Nicolas ^b   Rooney, Cliona ^b   Brenner, Malcolm ^b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; FIBRONECTIN; GREEN FLUORESCENT PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; OKT 3; RECOMBINANT INTERLEUKIN 2; RETRONECTIN; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; GENE THERAPY; HLA MATCHING; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENE; TUMOR ESCAPE; WESTERN BLOTTING;

EID: 4944243251     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-11-3803     Document Type: Article

References (58)

1. Kast WM, Offringa R, Peters PJ, et al. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell. 1989;59:603-614.
2. Rodolfo M, Bassi C, Salvi C, Parmiani G. Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours. Cancer Immunol Immunother. 1991;34:53-62.
3. Feltkamp MC, Vreugdenhil GR, Vierboom MP, et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol. 1995;25:2638-2642.
4. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549-1555.
5. Rosenberg IL, Smart DA, Gilfillan AM, Rooney SA. Effect of 1-oleoyl-2-acetylglycerol and other lipids on phosphatidylcholine synthesis and cholinephosphate cytidylyltransferase activity in cultured type M pneumocytes. Biochim Biophys Acta. 1987;921:473-480.
6. Mitchell MS, Darrah D, Yeung D, et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol. 2002;20:1075-1086.
7. Visonneau S, Cesano A, Porter DL, et al. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clin Cancer Res. 2000;6:1744-1754.
8. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor- infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159-1166.
9. Pockaj BA, Sherry RM, Wei JP, et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide and correlation with response. Cancer. 1994;73:1731-1737.
10. Siddiqa A, Sims-Mourtada JC, Guzman-Rojas L, et al. Regulation of CD40 and CD40 ligand by the AT-hook transcription factor AKNA. Nature. 2001;410:383-387.
11. Segerman A, Mei YF, Wadell G. Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines. J Virol. 2000;74:1457-1467.
12. Faucon N, Ogier G, Chardonnet Y. Changes in human adenovirus 5 propagated in Burkitt's lymphoma cells. J Natl Cancer Inst. 1982;69:1215-1220.
13. Andiman WA, Miller G. Persistent transduction with adenovirus types 5 and 6 in lymphoid cells from humans and woolly monkeys. J Infect Dis. 1982;145:83-88.
14. Chu Y, Sperber K, Mayer L, et al. Persistent transduction of human adenovirus type 5 in human monocyte cell lines. Virology. 1992;188:793-800.
15. Yotnda P, Onishi H, Heslop HE, et al. Efficient transduction of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001;8:930-937.
16. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol. 2000;74:2567-2583.
17. Roskrow MA, Suzuki N, Gan Y, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998;91:2925-2934.
18. Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice. J Exp Med. 1996;183:1215-1228.
19. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus transduction by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
20. DiMaio JM, Van Trigt P, Gaynor JW, et al. Generation of tumor-specific T lymphocytes for the treatment of posttransplant lymphoma. Circulation, 1995;92(suppl 9):II202-II205.
21. Smith CA, Ng CY, Heslop HE, et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995;4:73-79.
22. Brown MP, Topham DJ, Sangster MY, et al. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med. 1998;4:1253-1260.
23. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998;72:9706-9713.
24. Hemmi S, Geertsen R, Mezzacasa A, Peter I, Dummer R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther. 1998;9:2363-2373.
25. Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res. 2000;60:5031-5036.
26. Li Y, Pong RC, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 1999;59:325-330.
27. Rechner H, Wang X, Wang H, et al. Transcomplementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. Gene Ther. 2000;7:1954-1968.
28. Raper SE, Yudkoff M, Chirmule N, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther. 2002;13:163-175.
29. Stephenson J. Studies illuminate cause of fatal reaction in gene-therapy trial. JAMA. 2001;285:2570.
30. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus intemalization but not virus attachment. Cell. 1993;73:309-319.
31. Bergelson JM, Krithivas A, Celi L, et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol. 1998;72:415-419.
32. Wu H, Seki T, Dmitriev I, et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther. 2002;13:1647-1653.
33. Hidaka C, Milano E, Leopold PL, et al. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest. 1999;103:579-587.
34. Yee D, McGuire SE, Brunner N, et al. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther. 1996;7:1251-1257.
35. Brand K, Arnold W, Bartels T, et al. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther. 1997;4:9-16.
36. Huard J, Lochmuller H, Acsadi G, Jani A, Massie B, Karpati G. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 1995;2:107-115.
37. Kass-Eisler AA, Falck-Pedersen E, Elfenbein DH, Alvira M, Buttrick PM, Leinwand LA. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1994;1:395-402.
38. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA. 1993;90:2812-2816.
39. Lozier JN, Metzger ME, Donahue RE, Morgan RA. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood. 1999;94:3968-3975.
40. Bilbao R, Bustos M, Alzuguren P, et al. A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds. Gene Ther. 2000;7:1824-1832.
41. Kuppen PJ, van der Eb MM, Jonges LE, et al. Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer. Histochem Cell Biol. 2001;115:67-72.
42. thor Straten P, Becker JC, Guldberg P, Zeuthen J. In situ T cells in melanoma. Cancer Immunol Immunother. 1999;48:386-395.
43. Koehne G, Doubrovin M, Doubrovina E, et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol. 2003;21:405-413.
44. Seiter S, Monsurro V, Nielsen MB, et al. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J Immunother. 2002;25:252-263.
45. Lode HN, Xiang R, Dreier T, et al. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood. 1998;91:1706-1715.
46. Fargeas C, Wu CY, Nakajima T, Cox D, Nutman T, Delespesse G. Differential effect of transforming growth factor beta on the synthesis of Th1- and Th2-like lymphokines by human T lymphocytes. Eur J Immunol. 1992;22:2173-2176.
47. Beck C, Schreiber H, Rowley D. Role of TGF-beta in immune-evasion of cancer. Microsc Res Tech. 2001;52:387-395.
48. Yotnda P, Mintz P, Grigoriadou K, et al. Analysis of T-cell defects in the specific immune response against acute lymphoblastic leukemia cells. Exp Hematol. 1999;27:1375-1383.
49. Spector DJ, Halbert DN, Raskas HJ. Regulation of integrated adenovirus sequences during adenovirus transduction of transformed cells. J Virol. 1980;36:860-871.
50. Engelhardt JF, Litzky L, Wilson JM, Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther. 1994;5:1217-1229.
51. Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV transduction. Blood. 2002;100:4059-4066.
52. Heslop HE, Perez M, Benaim E, et al. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J Clin Apheresis. 1999;14:154-156.
53. Gervois N, Guilloux Y, Diez E, Jotereau F. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med. 1996;183:2403-2407.
54. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol. 2003;3:609-620.
55. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res. 2002;62:1063-1068.
56. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002;3:999-1005.
57. Bai XF, Liu J, Li O, Zheng P, Liu Y. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest. 2003;111:1487-1496.
58. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255-256.